• A
  • A
  • A
日本語 Help
Science and technology information site for articles, patents, researchers information, etc.
Advanced
search
ALL

Synonyms(0)

Find out more technical terms

Thesaurus Map Clips

ー



Please login to MyJ-GLOBAL to use J- GLOBAL.
Please register to create your MyJ-GLOBAL account, if you do not have one.
What is MyJ-GLOBAL?
Login Register now
Number of clips is over the max size. (Max number of Clips: 600)
Close
Reset
Go to 「How to search」 page
Advanced search: Search from
　
　Select basic information for advanced search
Free word
～
Chemical structure search
How to Search
NEW R FG i
C N O S F Cl Br I P X
JSME Molecular Editor by Peter Ertl and Bruno Bienfait
drag out MOL or RXN file
Import

MOLfile format is only available (V3000 format is not available)

              
Rchr
J-GLOBAL ID：201801019564208028   Update date: Apr. 22, 2025

Akimasa Sanagawa

サナガワ アキマサ | Akimasa Sanagawa
Affiliation and department：
Mie University Hospital

About Mie University Hospital


Research field  (4)： Clinical pharmacy ,  Cell biology ,  Nephrology ,  Tumor biology
Research keywords  (11)： 薬学 ,  毒性学 ,  ミトコンドリア ,  Chemical genetics ,  Off-target effects ,  構造活性相関 ,  ケミカルバイオロジー ,  がん代謝 ,  薬剤性腎障害 ,  Onco-nephrology ,  医薬品安全性評価
Research theme for competitive and other funds  (8)：
  • 2023 - 2027 がん分子標的薬による腎障害の発現機序解明:BRAF阻害剤に着目した検討
  • 2024 - 2025 Effects of Body Mass Index on Hypertriglyceridemia Associated with Oral Bexarotene Therapy: A Post Hoc Analysis of an Open-Label Comparative Clinical Study of Combined Bexarotene and Phototherapy Versus Bexarotene Monotherapy for Japanese Patients with Cutaneous T-Cell Lymphoma
  • 2023 - 2024 BRAF阻害剤ベムラフェニブの腎組織・細胞動態解析
  • 2022 - 2023 がん分子標的薬ベムラフェニブに関連した尿細管細胞死メカニズムの解明
  • 2021 - 2023 選択的BRAF阻害剤のポドサイト保護・毒性作用を決定付ける真の標的分子の同定
Show all
Papers (26)：
  • Akimasa Sanagawa, Hiroshi Takase. Increased mitochondrial superoxide level is partially associated with vemurafenib-induced renal tubular toxicity. Basic & Clinical Pharmacology & Toxicology. 2025. 136. 4. e70015
  • Akimasa Sanagawa, Tomoaki Hayakawa, Aya Yamamoto, Yuji Hotta, Yoko Furukawa-Hibi, Akimichi Morita. Effects of Body Mass Index on Hypertriglyceridemia Associated with Oral Bexarotene Therapy: A Post Hoc Analysis of an Open-Label Comparative Clinical Study of Combined Bexarotene and Phototherapy Versus Bexarotene Monotherapy for Japanese Patients with Cutaneous T-Cell Lymphoma. Drugs in R&D. 2024
  • Yuko Yamamoto, Masahiro Kondo, Yuji Hotta, Yuusuke Tashiro, Akimasa Sanagawa, Tomaya Kataoka, Yoko Furukawa-Hibi, Masaki Ri, Hirokazu Komatsu, Shinsuke Iida, et al. The Relationship between Changes in Serum Element Concentrations and Pathological Condition and Disease Status in Japanese Multiple Myeloma Patients: A Pilot Study and Literature Review. Asian Pacific Journal of Cancer Prevention. 2023. 24. 7. 2493-2503
  • Akimasa Sanagawa, Tomoaki Hayakawa, Emi Nishida, Aya Yamamoto, Kyoko Ikumi, Yukari Mori, Yuji Hotta, Kazunori Kimura, Yoko Furukawa-Hibi, Akimichi Morita. Impact of body mass index on the severity of bexarotene-associated hypertriglyceridemia: A post hoc analysis of an open-labeled clinical study of combined bexarotene and phototherapy in Japanese patients with cutaneous T-cell lymphoma. The Journal of Dermatology. 2023. 50. 7. 917-926
  • Yuko Yamamoto, Yuji Hotta, Natsumi Tomita, Aya Naiki-Ito, Ayae Kitagawa, Urara Kuboshiki, Tamaki Hagita, Misuzu Noda, Akimasa Sanagawa, Tomoya Kataoka, et al. Changes in zinc and manganese concentrations in cisplatin-induced acute kidney injury. Biochemistry and biophysics reports. 2023. 33. 101422-101422
ｍore...
MISC (3)：
Lectures and oral presentations  (65)：
  • BRAF阻害剤ベムラフェニブの尿細管毒性にスーパーオキシドが部分的に関与する
    (第34回日本医療薬学会年会 2024)
  • 患者中心の薬物療法を提供する能力の習得を志向した薬学実務実習の学習方略の構築
    (第34回日本医療薬学会年会 2024)
  • 薬物治療を個別最適化する能力の習得を志向した薬学実務実習の学習方略の構築
    (日本病院薬剤師会東海ブロック・日本薬学会東海支部合同学術大会2024 2024)
  • ベキサロテン関連高トリグリセリド血症に及ぼすBMIの影響:ベキサロテン単剤とベキサロテン+光線療法の比較試験データにおける検証
    (医療薬学フォーラム2024/第32回クリニカルファーマシーシンポジウム 2024)
  • cGMPが腎線維芽細胞に与える影響に関する検討
    (第24回抗加齢医学会総会 2024)
ｍore...
Education (2)：
  • 2014 - 2018 Nagoya City University Graduate School of Pharmaceutical Sciences
  • 2007 - 2013 Nagoya City University
Professional career (1)：
  • 博士(薬学) (名古屋市立大学)
Work history (6)：
  • 2025/04 - 現在 Mie University Hospital
  • 2023/04 - 2025/03 Nagoya City University Graduate School of Medical Sciences Department of Clinical Pharmaceutices & Therapeutices
  • 2020/10 - 2025/03 名古屋市立大学病院 薬剤部 薬剤師(兼務)
  • 2020/10 - 2023/03 名古屋市立大学大学院薬学研究科 病院薬剤学分野 病院助教
  • 2018/04 - 2020/09 Nagoya City University Graduate School of Pharmaceutical Sciences
Show all
Committee career (1)：
  • 2017/04 - 2020/04 愛知県病院薬剤師会 学術教育委員会 委員
Awards (2)：
  • 2023/07 - 医療薬学フォーラム2023/第31回クリニカルファーマシーシンポジウム 優秀ポスター賞
  • 2014/09 - 第24回日本医療薬学会年会 優秀演題賞
Association Membership(s) (4)：
THE JAPANESE SOCIETY OF TOXICOLOGY ,  THE PHARMACEUTICAL SOCIETY OF JAPAN ,  JAPANESE SOCIETY OF PHARMACEUTICAL HEALTH CARE AND SCIENCES ,  日本病院薬剤師会
※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page

TOP

BOTTOM